These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19513066)

  • 1. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
    Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
    Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
    Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
    Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
    Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
    Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
    van Oosterwijk JG; van Ruler MA; Briaire-de Bruijn IH; Herpers B; Gelderblom H; van de Water B; Bovée JV
    Br J Cancer; 2013 Sep; 109(5):1214-22. PubMed ID: 23922104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
    Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
    Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
    J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src: a potential target for the treatment of triple-negative breast cancer.
    Tryfonopoulos D; Walsh S; Collins DM; Flanagan L; Quinn C; Corkery B; McDermott EW; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy MJ
    Ann Oncol; 2011 Oct; 22(10):2234-40. PubMed ID: 21357651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
    Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
    Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
    Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
    Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Eustace AJ; Crown J; Clynes M; O'Donovan N
    J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
    Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
    Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
    Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.
    Kurebayashi J; Kanomata N; Moriya T; Kozuka Y; Watanabe M; Sonoo H
    BMC Cancer; 2010 Oct; 10():568. PubMed ID: 20959018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
    Park BJ; Whichard ZL; Corey SJ
    Cancer Lett; 2012 Jul; 320(1):104-10. PubMed ID: 22306341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
    Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
    Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases.
    Mohammed S; Shamseddine AA; Newcomb B; Chavez RS; Panzner TD; Lee AH; Canals D; Okeoma CM; Clarke CJ; Hannun YA
    Breast Cancer Res; 2021 Jul; 23(1):76. PubMed ID: 34315513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.